SCHEMBL24748942

SCHEMBL24748942

COC(=O)c1c(C(=O)OC)c2c(C)cc(C)cn2c1C(=O)c1ccc(OC)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ KDM4E B2RXH2 4/20 0.39
▸ ALDH1A1 P00352 5/20 0.38
▸ HPGD P15428 3/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ NPSR1 Q6W5P4 2/20 0.38
▸ TSHR P16473 2/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ MAPT P10636 4/20 0.38
▸ KMT2A Q03164 4/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ MAPK1 P28482 2/20 0.38
▸ LMNA P02545 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38
▸ PKM P14618 1/20 0.37
▸ ALOX15 P16050 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24749862 0.91 TDP1 (0.44) KDM4EALDH1A1GAATSHRCYP2C9
SCHEMBL24748979 0.88 KDM4E (0.39) KDM4EALDH1A1HPGDNPSR1TSHR
SCHEMBL24748614 0.88 CYP1A2 (0.43) KDM4EALDH1A1HPGDNPSR1TSHR
SCHEMBL24748595 0.85 KDM4E (0.38) KDM4EALDH1A1CYP3A4MAPTKMT2A
SCHEMBL30883370 0.71 KDM4E (0.51) CA1CA2KDM4EALDH1A1HPGD
SCHEMBL24748998 0.71 KLF10 (0.41) CA2KDM4EALDH1A1HPGDGAA
SCHEMBL9726568 0.71 HPGD (0.55) CA1CA2ALDH1A1HPGDGAA
SCHEMBL24750112 0.69 ALOX15 (0.40) ALDH1A1GAANPSR1LMNAALOX15
SCHEMBL28103002 0.68 KDM4E (0.49) CA1CA2KDM4EALDH1A1HPGD
SCHEMBL30816117 0.68 RAB9A (0.42) CA1CA2KDM4EALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11974991-B1 Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates King Faisal University (SA) 2024-05-07 — — US disclosed
US-11530217-B1 Antitubercular compounds King Faisal University (SA) 2022-12-20 — — US disclosed
US-11530217-B1 Antitubercular compounds King Faisal University (SA) 2022-12-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11974991-B1 Adenosine receptor activity of methyl/ethyl 3-(substituted benzoyl)-6,8-dimethylindolizine-2-substituted-1-carboxylates ADORA2A, ADORA1, ADORA3 CA1 4108/4885CA2 2959/4885KDM4E 2435/4885
US-11530217-B1 Antitubercular compounds MT-CO3, NOS3, MT-ND3 CA1 4323/4885CA2 1229/4885KDM4E 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback